Halozyme Therapeutics (HALO) Insider Trading & Ownership $45.70 -0.06 (-0.13%) (As of 11/21/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Halozyme Therapeutics (NASDAQ:HALO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.40%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$9.06 M Get HALO Insider Trade Alerts Want to know when executives and insiders are buying or selling Halozyme Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address HALO Insider Buying and Selling by Quarter Ad Genesis Gold GroupBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now Halozyme Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/16/2024Michael J LabarreSVPSell10,000$53.26$532,600.00 10/9/2024Helen TorleyCEOSell10,000$52.58$525,800.00 9/25/2024Helen TorleyCEOSell10,000$56.34$563,400.00 9/18/2024Michael J LabarreSVPSell10,000$62.03$620,300.00 9/12/2024Helen TorleyCEOSell10,000$59.20$592,000.00 9/10/2024Helen TorleyCEOSell10,000$59.09$590,900.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 9/9/2024Josh GottheimerU.S. Congress Member (D-NJ)Sell$59.24$1,001 - $15,0008/21/2024Michael J LabarreSVPSell10,000$61.75$617,500.00 8/14/2024Matthew L PosardDirectorSell9,881$57.70$570,133.70 8/12/2024Matthew L PosardDirectorSell10,000$55.72$557,200.00 7/24/2024Michael J LabarreSVPSell10,000$55.12$551,200.00 7/22/2024Nicole LabrosseCFOSell5,000$53.93$269,650.00 6/27/2024Nicole LabrosseCFOSell10,000$51.93$519,300.00 6/11/2024Matthew L PosardDirectorSell10,000$50.01$500,100.00 5/22/2024Michael J LabarreSVPSell10,000$45.38$453,800.00 4/17/2024Michael J LabarreSVPSell10,000$38.49$384,900.00 3/12/2024Michael J LabarreSVPSell10,000$41.64$416,400.00 2/28/2024Michael J LabarreSVPSell10,000$39.55$395,500.00 12/12/2023Michael J LabarreSVPSell10,000$39.63$396,300.00 (Data available from 1/1/2013 forward) HALO Insider Trading Activity - Frequently Asked Questions Who is on Halozyme Therapeutics's Insider Roster? The list of insiders at Halozyme Therapeutics includes Helen Torley, James M Daly, Jeffrey William Henderson, Matthew L Posard, Michael J Labarre, and Nicole Labrosse. Learn more on insiders at HALO. What percentage of Halozyme Therapeutics stock is owned by insiders? 2.40% of Halozyme Therapeutics stock is owned by insiders. Learn more on HALO's insider holdings. Which Halozyme Therapeutics insiders have been selling company stock? The following insiders have sold HALO shares in the last 24 months: Helen Torley ($7,021,264.86), James M Daly ($874,500.00), Jeffrey William Henderson ($477,100.00), Matthew L Posard ($2,772,833.70), Michael J Labarre ($9,167,900.00), and Nicole Labrosse ($913,331.50). How much insider selling is happening at Halozyme Therapeutics? Insiders have sold a total of 438,467 Halozyme Therapeutics shares in the last 24 months for a total of $21,226,930.06 sold. Which members of congress are trading Halozyme Therapeutics? Josh Gottheimer (D-NJ) has sold shares of Halozyme Therapeutics in the last year totaling $8,000. Halozyme Therapeutics Key ExecutivesDr. Helen I. Torley M.B. Ch. B. (Age 61)M.R.C.P., President, CEO & Director Compensation: $1.82MMs. Nicole LaBrosse (Age 41)Senior VP & CFO Compensation: $849.36k2 recent tradesDr. Michael J. LaBarre Ph.D. (Age 60)Senior VP & CTO Compensation: $843.89kMr. Mark Snyder Esq.Senior VP & Chief Legal OfficerMs. Cortney Caudill M.B.A.Chief Operations OfficerMs. Tram BuiHead of Investor Relations & Corporate CommunicationsMs. Amy Marinne FoxChief Human Resources OfficerMr. Gary GroteChief Commercial OfficerDr. Christopher Wahl M.B.A.M.D., Chief Business Officer More Insider Trading Tools from MarketBeat Related Companies IOVA Insider Buying TWST Insider Buying RLAY Insider Buying ADPT Insider Buying ALLO Insider Buying KOD Insider Buying FATE Insider Buying BIIB Insider Buying UTHR Insider Buying INCY Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:HALO) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredA “Thank You Gift” From Pres. Trump - GeniusTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredBREAKING: NVDA loses $175 billion in 8 minutesIt's a wild week for the legendary chipmaker. Nvidia just beat earnings expectations across every metric, w...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
